Results 221 to 230 of about 30,003 (287)

Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors [PDF]

, 2013
Michael Schmitt, Xiangdong Xu, Inken Hilgendorf, C Schneider, K Borchert, Dietrich Gläser, Mathias Freund, Anita Schmitt   +7 more
openalex   +1 more source

Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase. [PDF]

BioDrugs
Shibata H, Harazono A, Kiyoshi M, Saito Y, Ishii-Watabe A.   +4 more
europepmc   +1 more source

Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012

, 2012
Jonathan Kay, Brian G. Feagan, Micheal Guirguis, Edward Keystone, Ágnes Klein, A. S. Lubiniecki, Diane R. Mould, Kwasi A. Nyarko, Anthony A.G. Ridgway, Maureen Trudeau, Jian Wang   +10 more
openalex   +1 more source

Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies. [PDF]

PLoS One
Mizuno T, Kato Y, Tsukui T, Igase M.
europepmc   +1 more source

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) [PDF]

, 2013
Silvio Danese, Fernando Gomollón
openalex   +1 more source

Biosimilar monoclonal antibodies—challenges and opportunities in Europe [PDF]

, 2013
Andrea Laslop
openalex   +1 more source

The impact of biosimilar use on healthcare utilization among new users of etanercept for inflammatory arthritis: a population-based regression discontinuity analysis. [PDF]

Lancet Reg Health Am
Zhou VY, Lacaille D, Zheng Y, Qian Y, Nosyk B, Xie H.   +5 more
europepmc   +1 more source

Assessing biosimilarity using the method of generalized pivotal quantities [PDF]

, 2013
Shih‐Ting Chiu
openalex   +1 more source

Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013 [PDF]

, 2013
Antônio da Silva, Ulrich Kronthaler, Vera Koppenburg, Martin Fink, Ines Meyer, A. Papandrikopoulou, Matthias Hofmann, Thomas Stangler, Jan Marinus Visser   +8 more
openalex   +1 more source

Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review. [PDF]

Adv Ther
Wiland P, Both C, Gaylis NB, Cohen RD, Halfvarson J, Lemke L, von Richter O, Blauvelt A.   +7 more
europepmc   +1 more source